I. Laszlovszky

4.1k total citations
96 papers, 3.1k citations indexed

About

I. Laszlovszky is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, I. Laszlovszky has authored 96 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Psychiatry and Mental health, 26 papers in Cellular and Molecular Neuroscience and 18 papers in Molecular Biology. Recurrent topics in I. Laszlovszky's work include Schizophrenia research and treatment (53 papers), Neurotransmitter Receptor Influence on Behavior (23 papers) and Bipolar Disorder and Treatment (23 papers). I. Laszlovszky is often cited by papers focused on Schizophrenia research and treatment (53 papers), Neurotransmitter Receptor Influence on Behavior (23 papers) and Bipolar Disorder and Treatment (23 papers). I. Laszlovszky collaborates with scholars based in Hungary, United States and Austria. I. Laszlovszky's co-authors include Suresh Durgam, György Németh, Kaifeng Lu, Adam Ruth, Willie Earley, István Gyertyán, Raffaele Migliore, Ágota Barabássy, Anju Starace and Béla Kiss and has published in prestigious journals such as The Lancet, American Journal of Psychiatry and Neuroscience.

In The Last Decade

I. Laszlovszky

95 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Laszlovszky Hungary 31 2.2k 1.1k 595 533 396 96 3.1k
Josephine Cucchiaro United States 30 2.2k 1.0× 549 0.5× 596 1.0× 433 0.8× 285 0.7× 83 3.1k
Suresh Durgam United States 27 1.9k 0.9× 513 0.5× 605 1.0× 188 0.4× 391 1.0× 94 2.4k
L. Trevor Young Canada 26 1.9k 0.8× 623 0.6× 263 0.4× 739 1.4× 568 1.4× 41 3.2k
David C. Mamo Canada 36 2.5k 1.1× 1.1k 1.1× 700 1.2× 584 1.1× 406 1.0× 102 4.0k
Sanjay Dubé United States 20 1.4k 0.6× 449 0.4× 847 1.4× 399 0.7× 242 0.6× 48 2.6k
H.Y. Meltzer United States 27 1.9k 0.9× 1.1k 1.0× 420 0.7× 648 1.2× 644 1.6× 67 3.4k
Max Schmauß Germany 21 836 0.4× 659 0.6× 350 0.6× 355 0.7× 423 1.1× 101 2.3k
Alessandro Colasanti United Kingdom 27 635 0.3× 923 0.9× 289 0.5× 496 0.9× 936 2.4× 67 3.0k
Trisha Suppes United States 32 2.9k 1.3× 343 0.3× 592 1.0× 259 0.5× 981 2.5× 79 4.0k
Ross J. Baldessarini United States 21 1.4k 0.6× 481 0.4× 322 0.5× 324 0.6× 397 1.0× 27 2.3k

Countries citing papers authored by I. Laszlovszky

Since Specialization
Citations

This map shows the geographic impact of I. Laszlovszky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Laszlovszky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Laszlovszky more than expected).

Fields of papers citing papers by I. Laszlovszky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Laszlovszky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Laszlovszky. The network helps show where I. Laszlovszky may publish in the future.

Co-authorship network of co-authors of I. Laszlovszky

This figure shows the co-authorship network connecting the top 25 collaborators of I. Laszlovszky. A scholar is included among the top collaborators of I. Laszlovszky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Laszlovszky. I. Laszlovszky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kiss, Béla, et al.. (2022). Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo. Frontiers in Psychiatry. 13. 785592–785592. 7 indexed citations
2.
Laszlovszky, I., Béla Kiss, Ágota Barabássy, Margit Kapás, & György Németh. (2019). [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].. PubMed. 21(3). 103–118. 2 indexed citations
3.
Fava, Maurizio, Suresh Durgam, Willie Earley, et al.. (2018). Efficacy of adjunctive low-dose cariprazine in major depressive disorder. International Clinical Psychopharmacology. 33(6). 312–321. 43 indexed citations
4.
Ketter, Terence A., Roy H. Perlis, Suresh Durgam, et al.. (2017). The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. Journal of Affective Disorders. 225. 350–356. 29 indexed citations
5.
Earley, Willie, Suresh Durgam, Kaifeng Lu, et al.. (2017). Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. Journal of Affective Disorders. 215. 205–212. 25 indexed citations
6.
Earley, Willie, Suresh Durgam, Kaifeng Lu, et al.. (2017). Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia. International Clinical Psychopharmacology. 32(6). 319–328. 50 indexed citations
7.
Németh, György, I. Laszlovszky, Pál Czobor, et al.. (2017). Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. The Lancet. 389(10074). 1103–1113. 236 indexed citations
8.
Cutler, Andrew J., Suresh Durgam, Yao Wang, et al.. (2017). Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectrums. 23(1). 39–50. 47 indexed citations
9.
Durgam, Suresh, Willie Earley, Hua Guo, et al.. (2016). Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants. The Journal of Clinical Psychiatry. 77(3). 371–378. 92 indexed citations
10.
Citrome, Leslie, Suresh Durgam, Kaifeng Lu, Paul Ferguson, & I. Laszlovszky. (2016). The Effect of Cariprazine on Hostility Associated With Schizophrenia. The Journal of Clinical Psychiatry. 77(1). 109–115. 31 indexed citations
11.
Girgis, Ragy R., Mark Slifstein, Deepak Cyril D’Souza, et al.. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology. 233(19-20). 3503–3512. 97 indexed citations
12.
Durgam, Suresh, Robert E. Litman, Kelly Papadakis, et al.. (2015). Cariprazine in the treatment of schizophrenia. International Clinical Psychopharmacology. 31(2). 61–68. 57 indexed citations
13.
Durgam, Suresh, Anju Starace, Dayong Li, et al.. (2014). An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophrenia Research. 152(2-3). 450–457. 147 indexed citations
14.
Gyertyán, István, Béla Kiss, Krisztina Gál, et al.. (2006). Effects of RGH-237 [N-{4-[4-(3-Aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an Orally Active, Selective Dopamine D3 Receptor Partial Agonist in Animal Models of Cocaine Abuse. Journal of Pharmacology and Experimental Therapeutics. 320(3). 1268–1278. 29 indexed citations
15.
Sóvágó, Judit, Lars Farde, Christer Halldin, et al.. (2005). Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756. Brain Research Bulletin. 67(3). 219–224. 12 indexed citations
16.
Laszy, Judit, I. Laszlovszky, & István Gyertyán. (2004). Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology. 179(3). 567–575. 122 indexed citations
17.
Kovács, Krisztina, et al.. (2001). Double activity imaging reveals distinct cellular targets of haloperidol, clozapine and dopamine D3 receptor selective RGH-1756. Neuropharmacology. 40(3). 383–393. 24 indexed citations
18.
Vadász, C., et al.. (1996). Genomic characterization of two introgression strains (B6.Cb4i5) for the analysis of QTLs. Mammalian Genome. 7(7). 545–548. 11 indexed citations
19.
Vadász, Csaba, et al.. (1992). Genetic Aspects of Dopamine Receptor Binding in the Mouse and Rat Brain: An Overview. Journal of Neurochemistry. 59(3). 793–808. 16 indexed citations
20.
Buzsáki, György, I. Laszlovszky, Ábel Lajtha, & C. Vadász. (1990). Spike-and-wave neocortical patterns in rats: Genetic and aminergic control. Neuroscience. 38(2). 323–333. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josephine Cucchiaro Breakdown of academic impact, for papers by Suresh Durgam Breakdown of academic impact, for papers by L. Trevor Young Breakdown of academic impact, for papers by David C. Mamo Breakdown of academic impact, for papers by Sanjay Dubé Breakdown of academic impact, for papers by H.Y. Meltzer Breakdown of academic impact, for papers by Max Schmauß Breakdown of academic impact, for papers by Alessandro Colasanti Breakdown of academic impact, for papers by Trisha Suppes Breakdown of academic impact, for papers by Ross J. Baldessarini
Rankless by CCL
2026